Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP).

Détails

ID Serval
serval:BIB_CB8808099EA7
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP).
Périodique
International Journal of Radiation Oncology, Biology, Physics
Auteur(s)
Boccia R., Anné P.R., Bourhis J., Brizel D., Daly C., Holloway N., Hymes S., Koukourakis M., Kozloff M., Turner M., Wasserman T.
ISSN
0360-3016 (Print)
ISSN-L
0360-3016
Statut éditorial
Publié
Date de publication
2004
Peer-reviewed
Oui
Volume
60
Numéro
1
Pages
302-309
Langue
anglais
Notes
Publication types: Consensus Development Conference ; Journal Article ; Research Support, Non-U.S. Gov't ; Review Publication Status: ppublish
Résumé
PURPOSE: To review reports of severe skin reactions during amifostine treatment.
METHODS AND MATERIAL: The expert panel reviewed postmarketing reports of skin reactions and discussed strategies for evaluation and management.
RESULTS: Between 1994 and April 2002, 35 events were classified as severe skin reactions worldwide: erythema multiforme (8), Stevens-Johnson syndrome (10), toxic epidermal necrolysis (11), toxicoderma (3), and bullae (3). Unadjusted incidences were 6-9 per 10,000 radiotherapy patients and 0.8-1 per 10,000 chemotherapy patients. In 10 patients (29%) amifostine was continued after cutaneous signs and symptoms appeared.
CONCLUSIONS: Practical recommendations for practicing clinicians were developed. Cutaneous evaluation for rash, ulceration, or lesions-particularly on lips/mucosa, palmar/plantar surfaces, and the trunk-should be performed before amifostine administration. Reactions can be classified as local injection site/radiation port reactions or non-injection site reactions; and non-injection site reactions with associated fever or constitutional symptoms must be differentiated from radiation-induced dermatitis or cutaneous reaction with another etiology. Amifostine should be permanently discontinued for severe skin reactions or reactions associated with constitutional symptoms not known to be due to any other etiology. Increased physician awareness, proper patient management, monitoring before administration, and early intervention/discontinuation for non-injection site reactions may reduce the incidence of cutaneous reactions and enhance amifostine safety.
Mots-clé
Adolescent, Adult, Aged, Aged, 80 and over, Amifostine/adverse effects, Blister/chemically induced, Blister/epidemiology, Child, Child, Preschool, Drug Eruptions/epidemiology, Drug Eruptions/etiology, Erythema Multiforme/chemically induced, Erythema Multiforme/epidemiology, Humans, Incidence, Middle Aged, Product Surveillance, Postmarketing, Radiation-Protective Agents/adverse effects, Stevens-Johnson Syndrome/chemically induced, Stevens-Johnson Syndrome/epidemiology
Pubmed
Web of science
Création de la notice
01/12/2014 18:47
Dernière modification de la notice
03/03/2018 21:26
Données d'usage